Welcome to our dedicated page for Merus SEC filings (Ticker: MRUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Multispecific antibodies may revolutionize cancer therapy, but the disclosures behind Merus N.V.’s Biclonics® platform are anything but simple. From detailed phase 1/2 trial updates to collaboration milestone accounting, Merus filings can overwhelm even seasoned biotech analysts.
Stock Titan’s AI-powered analysis turns that complexity into clarity. Need the Merus quarterly earnings report 10-Q filing? We surface R&D burn rates and cash runway in seconds. Hunting for Merus insider trading Form 4 transactions or monitoring Merus executive stock transactions Form 4? Real-time alerts appear moments after EDGAR posts—no manual refresh required. Our platform also delivers plain-English digests so you’re understanding Merus SEC documents with AI rather than wading through legal jargon.
Every submission, from an 8-K announcing fresh clinical data to the comprehensive 10-K, is mapped to the questions investors actually ask:
- Merus annual report 10-K simplified – find pipeline timelines, collaboration revenue splits, and risk factors in one click.
- Merus 8-K material events explained – track trial readouts, FDA designations, or new licensing deals instantly.
- Merus proxy statement executive compensation – compare leadership incentives to R&D milestones.
Whether you’re performing a quick Merus earnings report filing analysis or need Merus Form 4 insider transactions real-time, Stock Titan provides comprehensive coverage and AI-generated summaries that answer, "Are insiders buying ahead of data?" or "How long will cash last at current burn?" Investors save hours, gain confidence, and never miss a disclosure that could move the stock.
Genmab Holding II B.V., a wholly owned subsidiary of Genmab A/S, commenced a cash tender offer to purchase all issued and outstanding common shares of Merus N.V. (MRUS) for $97.00 per share, less any applicable withholding taxes and without interest. The offer is made upon the terms and subject to the conditions set forth in the Offer to Purchase dated October 21, 2025, together with the accompanying Letter of Transmittal.
The filing lists related exhibits, including the Offer to Purchase, Letter of Transmittal, a media release announcing commencement, and a Debt Commitment Letter with Morgan Stanley Senior Funding, Inc. A Transaction Agreement among Genmab, the Purchaser, and Merus is referenced. Shareholders who tender and whose shares are accepted would receive cash consideration of $97.00 per share under the offer terms.
Merus N.V. entered a Transaction Agreement with Genmab A/S and its subsidiary Genmab Holding II B.V. dated September 29, 2025 under which Merus will become an indirect wholly owned subsidiary of Genmab following certain back‑end reorganization transactions and a subsequent closing.
At Genmab's request, Merus will delist its common shares from the Nasdaq Stock Market and deregister the shares under the Exchange Act, ending its reporting obligations. The agreement provides that any Merus option with an exercise price per share below the offer consideration will vest at the acceptance time and be converted into a cash payment equal to the difference between the offer price and the exercise price multiplied by the underlying shares; options with exercise prices equal to or above the offer consideration will be cancelled for no consideration.
Parent intends to make the acquisition via a tender offer to be filed on Schedule TO; Merus will file a Schedule 14D-9 and a definitive proxy on Schedule 14A for an extraordinary general meeting. The filing cites Merus SEC filings including the Form 10-K for year ended December 31, 2024 (filed Feb 27, 2025) and a Form 10-Q for period ended June 30, 2025 as sources of risk factors and updated information.
Commodore Capital LP and Commodore Capital Master LP reported beneficial ownership of 3,525,000 common shares of Merus N.V. (CUSIP N5749R100), equal to 4.7% of the 75,565,138 shares outstanding used for the calculation. The filing shows shared voting power and shared dispositive power over all 3,525,000 shares and no sole voting or dispositive power. The Firm (Commodore Capital LP) is the investment manager to Commodore Capital Master LP, and Michael Kramarz and Robert Egen Atkinson are the managing partners who exercise investment discretion. The filing includes a certification that the shares were not acquired to change or influence control of Merus.
Merus N.V. (Common Stock, CUSIP N5749R100) is the subject of a Schedule 13G/A filed by Wellington entities reporting aggregate beneficial ownership of 3,726,723 shares, representing 5.01% of the class. The filing shows shared voting power of 3,358,050 shares and shared dispositive power of 3,726,723 shares, with no sole voting or dispositive power reported. The securities are owned of record by clients of Wellington's investment advisers and are described as held in the ordinary course of business; the filing certifies they were not acquired to change or influence control of the issuer.
FAQ
What is the current stock price of Merus (MRUS)?
What is the market cap of Merus (MRUS)?
